Anti-Fibrinolytic Drugs - Portugal

The Anti-Fibrinolytic Drugs market in Portugal is projected to achieve a revenue of US$36.71m in 2024.
Furthermore, it is anticipated that the revenue will experience a compound annual growth rate (CAGR 2024-2029) of 4.98%, leading to a market volume of US$46.81m by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue in this market, reaching US$9.86bn in 2024.
Portugal has seen a surge in the demand for anti-fibrinolytic drugs due to an aging population and an increase in surgical procedures.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Portugal has been experiencing steady growth over the past few years.

Customer preferences: Portuguese customers have been showing a growing interest in Anti-Fibrinolytic Drugs due to their ability to prevent excessive bleeding during surgeries and other medical procedures. Additionally, an aging population and an increase in chronic diseases have also contributed to the rising demand for these drugs.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Portugal is the increasing use of tranexamic acid, a type of anti-fibrinolytic drug, in various medical procedures. This is due to its effectiveness in reducing blood loss and transfusion requirements. Moreover, there has been a rise in the number of pharmaceutical companies investing in the development of new anti-fibrinolytic drugs, which is expected to further drive market growth.

Local special circumstances: The Portuguese healthcare system has been undergoing significant reforms in recent years, which has led to an increase in the availability and accessibility of healthcare services, including the use of Anti-Fibrinolytic Drugs. Additionally, the country's geographic location and close proximity to other European countries have made it an attractive market for pharmaceutical companies looking to expand their operations in the region.

Underlying macroeconomic factors: The Portuguese economy has been growing steadily over the past few years, which has led to an increase in disposable income and healthcare spending. Moreover, the country's membership in the European Union has provided it with access to a larger market and increased investment opportunities. These factors have contributed to the growth of the Anti-Fibrinolytic Drugs market in Portugal.In conclusion, the Anti-Fibrinolytic Drugs market in Portugal has been experiencing steady growth due to customer preferences for these drugs, the increasing use of tranexamic acid, the country's healthcare reforms, and the underlying macroeconomic factors.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.